Figure 6.

GSK126 alleviates lupus nephritis in NZW/NZB F1 mice. (A) Experimental setting. Briefly, 24–28 weeks old female NZB/NZW F1 mice were randomized and grouped based on their urinary protein levels. The mice were treated with GSK126 (50 mg/kg, i.p.), or vehicles, every other day for 4 weeks. Peripheral blood and 24-h urine were collected at indicated time points. Kidneys were harvested 2 days after the last treatment for histopathological analysis. (B) Kaplan-Meier survival curve (n ≥ 10 for each group). (C) Anti-dsDNA autoantibody in the plasma. (D) Twenty-four-hour urinary protein. (E) Representative pictures of renal H&E staining and immunofluorescent staining of glomerular deposition of immunocomplex. Renal histopathological scores were evaluated for the mice in GSK126 group (n = 10) and vehicle group (n = 5). GN, glomerulonephritis; TI, tubulointerstitial nephritis. (F) The levels of ISG15 mRNA and IFIT3 mRNA in the kidneys from the mice treated with GSK126 or vehicle. (A) Created with BioRender.com. (B) P value was determined by Log-rank test. (C–E right panel, F) Each dot represents individual mice. Data are presented as mean ± SEM. P values were determined by Mann-Whitney U-test.